Phage Display VHH Discovery Service

Phage Display Nanobody Discovery Service

Phage display is a proven approach for discovering target-specific VHH binders from highly diverse antibody libraries. By linking each displayed VHH to its corresponding genetic sequence, iterative selection and enrichment can be used to isolate nanobody candidates with desired target-binding properties.

NBbiolab provides an integrated Phage Display Nanobody Discovery Service covering VHH library construction, target-specific phage biopanning, positive clone screening, sequence analysis, and candidate validation. Our phage display platform supports flexible screening strategies based on antigen format and project objectives, including purified proteins, peptides, and cell-surface targets.

From initial library preparation to the identification of target-specific VHH sequences, the workflow is designed to efficiently narrow large VHH repertoires into qualified nanobody candidates for downstream research and development.

When to Use Phage Display

Phage display is particularly suitable for:

Early-stage nanobody discovery

Screening against diverse antigen types (protein, peptide, cell surface targets)

Rapid enrichment of binders from large libraries

Projects requiring high library diversity

Initial binder identification prior to affinity maturation

Our Phage Display VHH Discovery Workflow

Deliverables

Clients will receive

High-affinity VHH sequences

Clone information and sequence data

Binding validation results

Expression-ready constructs

Detailed project report

Optional downstream services

Nanobody humanization

Affinity maturation

Functional characterization

Typical Project Timeline

Stage	Delivery	Time
Library construction	Phage library	~4 weeks
Screening	Binder sequences + report	~4 weeks

Total timeline: 6–8 weeks
The timeline above covers the yeast display library construction and screening stages of nanobody discovery. If camelid immunization is required, an additional 6–8 weeks may be needed.

Phage Display Screening Strategies for Different Target Types

Different targets may require different screening strategies to efficiently enrich target-specific VHH binders. Our Phage Display VHH Discovery Service can adapt the selection format according to antigen type, target presentation, and project objectives.

Target Type	Screening Approach	Key Consideration
Purified Recombinant Proteins	Solid-phase or solution-phase biopanning	Supports enrichment of target-specific VHH binders under controlled selection conditions.
Biotinylated Proteins	Solution-phase screening	Allows antigen capture in solution and can help preserve native protein conformation.
Peptide Targets	Solid-phase phage biopanning	Suitable for epitope-focused VHH binder discovery against defined peptide sequences.
Cell-Surface Targets	Cell-based phage screening	Enables screening against targets presented in a more native cellular context.
Membrane-Associated Targets	Cell-based or customized selection	The screening strategy can be adjusted according to target accessibility and antigen presentation.

Selection conditions can also be adjusted between screening rounds to improve enrichment and reduce non-specific binders. The final strategy is determined according to antigen availability, target characteristics, and the intended downstream application.

How We Select VHH Candidates After Phage Display Screening

Successful phage display screening involves more than identifying positive clones. Following biopanning and initial binder screening, VHH candidates are evaluated from multiple perspectives to identify representative sequences for further validation and development.

Enrichment Across Screening Rounds

Changes in target-binding signals across successive phage biopanning rounds are evaluated to determine whether target-specific VHH populations are being successfully enriched.

Target-Specific Binding

Positive clones are screened against the target to identify VHH binders with reproducible binding signals while reducing non-specific background.

Sequence Diversity

Positive clones are sequenced and compared to identify unique VHH sequences, sequence families, and redundant clones. This helps preserve candidate diversity rather than selecting multiple copies of closely related binders.

Candidate Prioritization

Representative VHH candidates can be prioritized according to binding performance, sequence diversity, specificity, expression behavior, and other project-defined requirements. Selected candidates can then proceed to recombinant production and further characterization.

What Information Is Needed to Start a Phage Display VHH Discovery Project?

Providing clear target and project information at the beginning helps define an appropriate VHH phage display screening strategy and reduces unnecessary screening steps.

Useful project information includes:

Target name and biological background
Target type, such as soluble protein, peptide, membrane protein, or cell-surface target
Available antigen format and amount
Desired VHH binder characteristics
Intended research or therapeutic application
Preferred screening format, if already determined
Available positive or negative controls
Requirements for downstream expression, validation, or engineering

If the screening strategy has not yet been determined, our team can evaluate the antigen format and project objective to recommend an appropriate phage display VHH screening approach.

From VHH Discovery to Downstream Development

Phage display screening provides target-specific VHH sequences that can serve as starting candidates for further nanobody development. Depending on the project objective, selected binders can continue into recombinant production, characterization, or engineering workflows.

Nanobody Expression & Production

Selected VHH sequences can be transferred into suitable expression systems for recombinant protein production, purification, and QC. Learn more about our Nanobody Expression & Production service.

Nanobody Humanization

Camelid-derived VHH candidates intended for therapeutic development may require sequence engineering to reduce potential immunogenicity while maintaining important binding and developability properties. Learn more about our Nanobody Humanization Service.

Affinity Optimization

When further binding optimization is required, selected VHH candidates can enter an affinity maturation workflow using rational engineering and quantitative screening strategies. Learn more about our Antibody Affinity Maturation Service.

This integrated workflow allows projects to progress from initial Phage Display VHH Discovery to validated and engineered nanobody candidates according to downstream development requirements.

Start Your Phage Display VHH Discovery Project

Whether you are starting with a purified antigen, peptide, cell-surface target, or an existing VHH discovery strategy, our team can help design a screening workflow based on your target format and project goals.

Share your target information, available antigen format, intended application, and desired binder characteristics with us to discuss a customized Phage Display Nanobody Discovery Service strategy for your project.

Discuss Your VHH Discovery Project

Why Choose Our Phage Display VHH Discovery Service

High-Diversity Libraries

Library sizes up to 10⁹–10¹¹ ensure broad binder coverage

Optimized Biopanning Strategy

Customized panning conditions improve enrichment efficiency

Extensive Project Experience

Proven success across multiple target classes

Fast Turnaround Time

Efficient workflows reduce project timelines

FAQs

What are the phage display vector, host strain and helper phage adopted?

The phage display vector used is pComb3xss with HA and His tags; the host strain is TG1, and the helper phage is M13K07.

What are the quality control indicators for phage libraries?

Phage library quality control covers three aspects:
1. Library capacity calculated by transformants, reaching up to 10⁹ for phage libraries;
2. 100% insertion rate of target fragments;
3. Random selection of 48 clones for sequencing to evaluate library diversity.

Is nested PCR adopted for amplifying single-domain antibody genes for library construction? If yes, what are the amplification positions of primers in two rounds of nested PCR?

Nested PCR is used for single-domain antibody gene amplification in library construction. In the first round of nested PCR, the upstream primer targets the antibody signal peptide region and the downstream primer targets the CH2 region. In the second round, the upstream primer is located in the antibody FR1 region and the downstream primer in the hinge region.

What screening formats are available for phage display?

Common phage display screening formats include solid-phase screening, liquid-phase screening and cell-based screening.

Can phage display screen functionally active antibodies such as blocking antibodies?

Phage display is more inclined to screen binding antibodies, with inherent system limitations in screening functional antibodies (blocking, neutralizing and activating antibodies).

For screening blocking, neutralizing or activating antibodies, the positive control antibody can first be constructed into the phage vector to verify the applicability of the screening model and detection system. Formal screening can be launched only after system feasibility is confirmed.

Which sample form is adopted for screening and identification, phage supernatant or periplasmic protein?

Phage supernatant is preferred in the primary screening stage. Periplasmic protein is generally used for re-verification and activity identification of positive clones in the later stage.

Can monoclonal flow cytometry identification be performed in phage screening?

Flow cytometry-based binding identification of monoclonals with target cells is feasible. A phage-form positive control must be set in the experimental system to eliminate interference from background signals and non-specific binding.